Lung Cancer News

A novel liquid biopsy test can help determine whether patients with oligometastatic non-small cell lung cancer will benefit more from targeted, high-dose radiation instead of drug-based therapy, according to study results.

An FDA advisory committee voted 10-2 that the results of a confirmatory trial for the targeted lung cancer drug sotorasib cannot be interpreted reliably.

Takeda will work with the FDA toward voluntary withdrawal of its lung cancer therapy mobocertinib from the U.S. market, according to a company press release.

High-dose hyperfractionated thoracic radiotherapy with concurrent chemotherapy improved outcomes for patients with limited-stage small cell lung cancer, according to randomized phase 3 study results presented at ASTRO Annual Meeting.

Amivantamab plus lazertinib improved PFS compared with osimertinib as first-line therapy in adults with locally advanced or metastatic EGFR-mutated non-small cell lung cancer, according to the agent’s manufacturer.

The addition of nivolumab to neoadjuvant chemotherapy followed by adjuvant nivolumab extended EFS among patients with resectable non-small cell lung cancer, according to the agent’s manufacturer.

Two phase 3 trials evaluating a regimen containing pembrolizumab plus lenvatinib for treatment of metastatic non-small cell lung cancer failed to meet their primary endpoints, according to the manufacturers of each agent.

Osimertinib plus chemotherapy conferred significantly greater improvement in PFS compared with osimertinib alone in patients with EGFR-mutated advanced non-small cell lung cancer, according to study results.

The addition of benmelstobart and anlotinib to chemotherapy significantly improved median PFS and OS compared with chemotherapy alone among patients with extensive-stage small cell lung cancer, according to study results.

Prescription medications added onto tobacco longitudinal care did not improve long-term abstinence rates among current smokers eligible for lung cancer screening, according to results published in JAMA Network Open.